In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

Abstract

Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow therapeutic index and highly variable pharmacokinetics. This cross-sectional study in 59 renal transplant patients investigated the relationship among in vivo CYP3A4 activity (assessed using midazolam as a drug probe), CYP3A5 genotype on the one hand, and tacrolimus… (More)
DOI: 10.1038/clpt.2012.109

Topics

3 Figures and Tables

Cite this paper

@article{Jonge2012InVC, title={In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.}, author={Hylke de Jonge and Henriette de Loor and Kirstin Verbeke and Yves F Ch Vanrenterghem and Dirk Kuypers}, journal={Clinical pharmacology and therapeutics}, year={2012}, volume={92 3}, pages={366-75} }